GALT - galectintherapeutics.com Debt to Book Capitalization Ratio

This accompanying price chart illustrates the price action of Galectin Therapeutics (GALT), whose business relies on developing cost-effective drugs with massive global profit potential, which constitutes 0.00. The company's strategy is based on simultaneously targeting oncology and cirrhosis, which minimizes the risks of licensing delays. The market is currently in a mode of cautious anticipation regarding test results, upon which the final brand recognition depends.

GALT (Galectin Therapeutics Inc.) Debt to Book Value history from 07/04/2022 to 10/28/2026

galectintherapeutics.com (GALT) - metric breakdowns and financial figures

- price and consensus price forecast:

Stock Price Galectin Therapeutics Inc.|GALT - Analyst Consensus Forecast

- market capitalization data:

Market Value Galectin Therapeutics Inc.|GALT - Value Adjusted for Debt and Cash

- book capitalization data:

Net Assets per Single Share Galectin Therapeutics|GALT - Company Net Assets|Market Capitalization to Book Value Ratio galectintherapeutics.com|GALT - Company Total Assets

- debt and liquidity data:

Total Debt to Equity Ratio Galectin Therapeutics|GALT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Galectin Therapeutics Inc.|GALT - Company Debts|Debts to Book Capitalization Galectin Therapeutics Inc.

Fundamental company analysis:Galectin

Core merchandise of Galectin Therapeutics Inc.

Developing liver therapy drugs involves extreme risks and fierce competition, where any trial failure clears the path for pharmaceutical behemoths. The ratio of borrowed funds to the book value of assets quantifies the financial stability of Galectin Therapeutics (GALT), demonstrating the real margin of safety and bankruptcy risk during business scaling through the current leverage ratio to book capital.

Competitors of Galectin Therapeutics (GALT)